FDA
15th November 2013

FDA AdComm Roll Call – New Members!

This month we saw the departure of seven members and the addition of a total of 15 new members to the FDA Drug Advisory Committees. The committees that welcomed new members include the Anesthetic Drug Products Advisory Committee (AADP), the Antiviral Drugs Advisory Committee (AVD), the Pharmaceutical Science and Clinical Pharmacology Advisory Committee, and the Psychopharmacologic Drugs Advisory Committee.

FDA AdComm Roll Call – New Members!

This month we saw the departure of seven members and the addition of a total of 15 new members to the FDA Drug Advisory Committees. The committees that welcomed new members include the Anesthetic Drug Products Advisory Committee (AADP), the Antiviral Drugs Advisory Committee (AVD), the Pharmaceutical Science and Clinical Pharmacology Advisory Committee, and the Psychopharmacologic Drugs Advisory Committee.

The AADP welcomed five new members, filling five of six open spots. This committee is now down to just one vacancy and the new members include:

  • Michael R. Clark, MD, MBA, MPH, an Associate Professor in the Department of Psychiatry and Behavioral Sciences at the Johns Hopkins Hospital. Dr. Clark’s expertise is in Behavioral Medicine and Pain Management.
  • Charles W. Emala, Sr., MS, MD, an expert in anesthesiology, and a Professor and Vice-Chair for Research in the Department of Anesthesiology at the Columbia University College of Physicians & Surgeons
  • Alan D. Kaye, MD, PhD, a Professor and Chairman of the Department of Anesthesia at the Louisiana State University School of Medicine and an expert in Anesthesiology and Pain Services.
  • Gary A. Walco, PhD, also an expert in anesthesiology and Pain Medicine. Dr. Walco is a Professor of Anesthesiology and Pain Medicine at the University Of Washington School Of Medicine.
  •  Rafael V. Miguel, MD, whose area of expertise is in anesthesiology and pain medicine. Dr. Miguel is currently the President of a company called Brandon Pain Medicine, Inc.

The AVD saw the departure of four members, whose terms expired at the end of October. The committee wasted no time and immediately welcomed four new members:

  • Andrew Aronsohn, MD, an expert in hepatology and an Assistant Professor of Medicine
    University of Chicago Medical Center Center for Liver Diseases.
  • Dean Follmann, PhD, a Biostatistician, and Assistant Director for Biostatistics at the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH).
  • Jonathan Honegger, MD, an Assistant Professor of Pediatrics at The Ohio State University College of Medicine. Dr. Honegger’s expertise is in Pediatric Infectious Disease.
  • Vincent Lo Re, MD, MSCE, an expert in infectious disease and Assistant Professor of Medicine and Epidemiology at the Perelman School of Medicine, University of Pennsylvania.

Leaving the Pharmaceutical Science and Clinical Pharmacology Advisory Committee were three members. Four more joined the committee which brings the total number of vacancies down from 18 to 17. The four new members include:

  • James C. Cloyd, Pharm.D., an expert in clinical pharmacology & orphan drug research and Director of the Center for Orphan Drug Research at the University of Minnesota.
  • Marilyn E. Morris, Ph.D., a Professor in the Department of Pharmaceutical Sciences at the
    University at Buffalo. Dr. Morris’ areas of expertise include Pharmaceutics, Pharmacokinetics, and Pharmacodynamics.
  • Kathleen A. Neville, M.D., M.S, the Director, Experimental Therapeutics in Pediatric Oncology Program at Children’s Mercy Hospitals and Clinics. Dr. Neville is an expert in Clinical Pharmacology and Pediatric Hematology/Oncology; she is also an Associate Professor of Pediatrics at the University of Missouri.
  • Anne S. Robinson, Ph.D., a chemical engineer, and Chair of the Department of Chemical and Biomolecular Engineering at Tulane University.

We also saw the addition of Dr’s Battisti and Maddock to the Psychopharmacologic Drugs Advisory Committee. John J. Battisti, Ph.D., R.Ph.’s expertise is in Neuropharmacology and he is currently an Associate Professor of Clinical Sciences at the College of Pharmacy of Calilfornia Northstate University. Richard J. Maddock, M.D. is a Psychiatrist and is currently a Professor at the University of California Davis. The number of vacancies in this committee is now down from five to three.

Want to stay up to date on the members of the FDA Drug Advisory Committees?
Subscribe to the ISS AdComm Blog now!

Follow AdComm Blog

ISS has over a decade of experience in developing regulatory strategies including support for FDA Advisory Committee meetings. We are involved in more FDA AdComms per year than even the largest pharmaceutical companies. For more information on how ISS can help you prepare for your next meeting, contact info@innovativescience.net

Recent Related Articles

Best Tips for Medical Device Manufacturers to Write a Compelling Substantial Equivalence Section for their FDA 510k Submission
01 July 2020
Best Tips for Medical Device Manufacturers to Write a Compelling Substantial Equivalence Section for their FDA 510k Submission

Over the past few years, the number of ex-US manufacturers submitting a Class II exempt 510k device registration has increased substantially. For companies with medical devices that are approved and successful in a foreign market, the logical next step is to introduce their product into the US, which has one of the most lucrative healthcare markets in the world. Read more

Evolving FDA Thinking on Advisory Committee Meetings Related to Foods, Drugs, and Devices
25 June 2020
Evolving FDA Thinking on Advisory Committee Meetings Related to Foods, Drugs, and Devices

FDA advisory committee meetings are important regulatory events for many manufacturers on the path to marketing approval. These meetings can quite literally result in the approval or rejection of a product based on the panel’s vote. Read more

NDA vs. OTC Monograph: Which Pathway is Right for You?
22 June 2020
NDA vs. OTC Monograph: Which Pathway is Right for You?

One of the main challenges our clients face is determining which regulatory pathway is best for their products. For example, what if an OTC product has a Monograph active ingredient but that ingredient is present at a different amount than the permitted amount? Or what if the label claims a novel indication not specified in a Monograph? If you are debating pursuit of either regulatory pathway for your OTC drug, it is critical to consider cost, timeline, and label claims to ensure your products has a unique stance in today’s market. Read more

4 Problems Importing Rapid Antibody Tests for Coronavirus
19 June 2020
4 Problems Importing Rapid Antibody Tests for Coronavirus

US distributors and agents trying to import rapid antibody tests for coronavirus face a number of obstacles. The good news is that FDA has opened up the Emergency Use Authorization (EUA) program to include SARS-CoV-2 (the virus) and COVID-19 (the disease), expediting time to market. Read more

Let’s work together

The journey to scientific and commercial success is often complex and always critical, if you are looking for an expert partner to help steer you to confident solutions, contact us today

Contact us